Stage

Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival

CHICAGO – June 2, 2007 – Long-term treatment withpegylated interferon alfa-2b in stage III melanoma had asignificant and sustained impact on relapse-free survival (RFS),according to the results of the largest adjuvant trial everconducted in patients with stage III melanoma. Results of the PhaseIII study, led by...

Introgen and Clinical Collaborators to Report New Results with Advanced-Stage Cancer Therapies at Upcoming Medical Meetings

AUSTIN, Texas--(BUSINESS WIRE)--May 29, 2007 - IntrogenTherapeutics, Inc. (NASDAQ:INGN) and the Company's clinicalcollaborators will report updated Phase 2 clinical trial resultsfor its lead cancer therapy product candidates at the upcomingannual meetings of The American Society of Clinical Oncology (ASCO)in Chicago and the American Society of Gene Therapy (ASGT) inSeattle. "We have a st...

FDA MedWatch: Avastin (bevacizumab) and Formation of Tracheoesophageal Fistula in a Recent Clinical Study in Patients with Limited-stage Small Cell Lung Cancer

ROCKVILLE, Md., April 21, 2007-Genentech and FDA notifiedhealthcare professionals of important new safety informationregarding tracheoesophageal (TE) fistula formation in a recentclinical study in patients with limited-stage small cell lungcancer (SCLC). This multicenter, non-randomized, single-arm phaseII clinical trial study combined chemotherapy and radiation plusAvastin. There have b...

Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage 2 Patients Compared With Amlodipine + Benazepril

Comparison of BENICAR HCT 40/12.5 and 40/25 mg/day and Amlodipine +Benazepril 5/20 and 10/20 mg/day Presented at American Society ofHypertension Twenty-Second Annual Scientific Meeting PARSIPPANY, N.J., May 21, 2007 /PRNewswire/ -- New datapresented today at the American Society of Hypertension'sTwenty-Second Annual Scientific Meeting (ASH 2007) in Chicagodemonstrated that the fixed-dose...

Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month Hematide for the Treatment of Anemia in Patients with Early- and End-Stage Chronic Kidney Disease

PALO ALTO, Calif.--(BUSINESS WIRE)--Apr 23, 2007 - Affymax, Inc.(Nasdaq:AFFY) today announced results to date from two separatePhase 2 clinical trials of Hematide(TM) in dialysis andnon-dialysis chronic kidney disease (CKD) patients. The data showedthat in treatment naive, non-dialysis patients Hematide couldcorrect anemia when administered monthly at an appropriate dose.Similarly, the data...

Chemokine Therapeutics Announces Preliminary Results of CTCE-9908 Phase Ib/II Clinical Trial in Late Stage Cancer Patients

TSX: CTI OTCBB: CHKT VANCOUVER, March 12, 2007 /PRNewswire-FirstCall/ - ChemokineTherapeutics Corp. ("Chemokine Therapeutics" or the "Company") , abiotechnology company developing chemokine-based therapies to treatcancer, blood disorders, and vascular disease today announcedpositive preliminary data and the successful completion of thedose-escalation portion of its Phase Ib/II clinical tr...